Tetraselmis chuii for Health & Longevity - Quick Reference Sheet

Tetraselmis chuii for Health & Longevity

Created on 10/15/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Tetraselmis chuii is a green marine alga used as an oral supplement for exercise recovery and cellular health. Moderate evidence from small, short, industry-funded studies shows low doses speed post-exercise strength recovery and higher doses improve sperm motility and live births in unexplained infertility. Endurance and body composition findings are conflicted. Low doses are well tolerated, while high doses caused minor blood shifts within normal limits. (Full Review)

Protocol

Standard low-dose protocol
25 mg/day
Freeze-dried Tetraselmis chuii strain CCFM03 (TetraSOD or Oceanix, ≥30,000 IU/g SOD) for exercise recovery and muscle NRF2/SIRT1 signaling
Alternative high-dose protocols
200 or 250 mg/day
200 mg/day for 30 days in athletes, or 250 mg/day (European Union supplement maximum) for 90 days in male infertility
Time of day and dosing frequency
Once daily (oral capsule)
Single daily capsule (never split-dosed) in the morning with breakfast (8:00–10:30 AM) or 30 minutes pre-workout
Time to effect
Post-Exercise Neuromuscular Recovery and Strength Preservation
14 days to 6 weeks
Post-exercise strength preservation, VO2peak gains, and muscle NRF2/SIRT1 upregulation emerge at 14 days; perceived recovery and force preservation over 6 weeks
Semen Quality and Live Birth Rate in Idiopathic Male Infertility
90 days
Progressive sperm motility and DNA fragmentation improvements at 90 days (250 mg/day); live birth outcomes tracked at 9-month follow-up
Erythropoiesis, Hematological Indices, and Anabolic Hormones
30–60 days
VO2max and hemoglobin shifts at 30 days (200 mg/day); erythropoietin, IGF-1, and lymphocyte shifts over 30–60 days

Benefits

Contraindications
  • Children and adolescents under 18 years of age
  • Pregnant and lactating women
  • Individuals with thrombocytopenia or active bleeding disorders
  • Individuals with uncontrolled gout or hyperuricemia (200 mg/day)
Key Interactions
  • Prescription anticoagulants and antiplatelets (warfarin, apixaban, rivaroxaban, clopidogrel): Caution (theoretical)
  • Over-the-counter antiplatelet and nonsteroidal anti-inflammatory drugs (aspirin, ibuprofen, naproxen): Monitor (theoretical)
  • Urate-lowering prescription medications (allopurinol, febuxostat, probenecid): Monitor (theoretical)
  • Antidiabetic medications (metformin, glimepiride, semaglutide, insulin): Monitor (theoretical)
  • Iodine-containing and antiplatelet supplements (kelp, potassium iodide, high-dose omega-3 fish oil, Ginkgo biloba): Monitor (theoretical)
  • High-volume resistance and eccentric exercise protocols: Potentiating interaction

Risk & Side Effects

  • High:
  • Medium:
  • Low: Elevations in fasting glucose, uric acid, and serum creatinine; reductions in platelet count and mean platelet volume
  • Speculative: Hepatic pro-inflammatory cytokine transcript upregulation; bioaccumulation of heavy metals and polycyclic aromatic hydrocarbons; purine-mediated hyperuricemia in susceptible individuals

Monitoring

Marker Target Why
Fasting Blood Glucose 70–99 mg/dL (standard reference range) Safety check: 200 mg/day raised fasting glucose (+8.0 mg/dL) in a 30-day trial; protocols reduce to 25 mg/day or stop if ≥100 mg/dL.
Serum Uric Acid 3.5–7.2 mg/dL in men; 2.6–6.0 mg/dL in women (standard reference range) Safety check: 200 mg/day increased serum uric acid in athletes; protocols discontinue use if uric acid rises above the upper reference limit.
Serum Creatinine 0.7–1.3 mg/dL in men; 0.6–1.1 mg/dL in women (standard reference range) Safety check: 200 mg/day elevated creatinine from 0.96 to 1.07 mg/dL; strenuous exercise is avoided for 24 hours before testing.
Platelet Count and Mean Platelet Volume (MPV) Platelets: 150–450 × 10³/µL; MPV: 7.5–11.5 fL (standard reference range) Safety check: two trials noted mild drops in platelet count or MPV; protocols stop if platelets drop below 150 × 10³/µL.
Serum Creatine Kinase (CK) No established target; 24–48 hour post-exercise attenuation tracked relative to individual baseline Expected to change: 25 mg/day lowered 24-hour post-damage log serum CK vs. placebo (sampled 24 hours post-exercise).
Countermovement Jump or Isometric RFD No established target; maintenance or recovery to ≥95% of individual baseline tracked Expected to change: 25 mg/day preserved 48-hour and 6-week rate of force development (RFD) on a force plate.

Cadence: Baseline (comprehensive metabolic panel, serum uric acid, complete blood count, and countermovement jump or isometric pull force); follow-up at 2 and 6 weeks for 25 mg/day regimens, and at 4, 8, and 12 weeks (then every 3 to 6 months if cycled) for 200 to 250 mg/day regimens, with discontinuation if no measurable benefit is evident by 6 to 8 weeks.

Qualitative Assessment

  • Perceived post-exercise recovery: Tracked weekly on the 0–10 Perceived Recovery Status (PRS) scale during intensive training blocks.
  • Delayed-onset muscle soreness and readiness: Assessed via subjective muscle soreness and jump readiness 24–48 hours after strenuous sessions.